Ubs Group Ag Design Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 14,880 shares of DSGN stock, worth $75,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,880

Previous 13,360 11.38%

Holding current value

$75,590

Previous $44,000 81.82%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $5.88 $4,848 - $8,937	1,520 Added 11.38%	14,880 $80,000
Q2 2024 Aug 13, 2024	SELL	$3.23 - $4.77 $63,543 - $93,840	-19,673 Reduced 59.56%	13,360 $44,000
Q1 2024 May 13, 2024	SELL	$2.27 - $4.03 $39,516 - $70,154	-17,408 Reduced 34.51%	33,033 $133,000
Q4 2023 Feb 09, 2024	BUY	$1.99 - $2.76 $64,430 - $89,360	32,377 Added 179.23%	50,441 $133,000
Q3 2023 Nov 09, 2023	SELL	$2.05 - $8.14 $12,500 - $49,637	-6,098 Reduced 25.24%	18,064 $42,000
Q2 2023 Aug 11, 2023	BUY	$4.99 - $7.64 $119,540 - $183,023	23,956 Added 11629.13%	24,162 $152,000
Q1 2023 May 12, 2023	SELL	$5.5 - $9.77 $857,015 - $1.52 Million	-155,821 Reduced 99.87%	206 $1,000
Q4 2022 Feb 08, 2023	BUY	$7.86 - $17.2 $1.23 Million - $2.68 Million	156,027 New	156,027 $1.6 Million
Q2 2022 Aug 10, 2022	SELL	$9.91 - $17.33 $9,890 - $17,295	-998 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.17 - $20.89 $10,756 - $20,117	963 Added 2751.43%	998 $16,000
Q4 2021 Feb 14, 2022	SELL	$13.64 - $21.41 $14,990 - $23,529	-1,099 Reduced 96.91%	35 $1,000
Q3 2021 Nov 15, 2021	BUY	$13.99 - $20.03 $8,897 - $12,739	636 Added 127.71%	1,134 $17,000
Q2 2021 Aug 13, 2021	BUY	$19.02 - $29.78 $3,765 - $5,896	198 Added 66.0%	498 $10,000
Q1 2021 May 12, 2021	BUY	$29.52 - $41.49 $8,856 - $12,447	300 New	300 $9,000

Others Institutions Holding DSGN

# of Institutions

102

Shares Held

31M

Call Options Held

2.3K

Put Options Held

16.5K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $284M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account